SIBO
Peptides discussed for SIBO — BPC-157, KPV, larazotide — with honest framing about why rifaximin remains primary therapy and where peptides may help with mucosal recovery and gut motility support.
Small intestinal bacterial overgrowth (SIBO) is a condition of excessive bacterial colonization of the small intestine, where bacterial counts should normally be low. The clinical syndrome includes bloating, abdominal pain, distension, altered bowel habits (diarrhea, constipation, or alternating), nutrient malabsorption (B12, iron, fat-soluble vitamins), and often coexisting irritable bowel syndrome. The diagnosis is made by glucose or lactulose breath testing measuring hydrogen and methane production after a sugar challenge, with patterns distinguishing hydrogen-dominant SIBO from methane-dominant SIBO/IMO (intestinal methanogen overgrowth).
Conventional first-line treatment is antibiotic therapy — rifaximin (a non-absorbable antibiotic effective against many gut bacteria) for hydrogen-dominant SIBO, often combined with neomycin for methane-dominant disease. Adjunctive interventions include prokinetic agents (low-dose erythromycin, prucalopride) to support migrating motor complex activity, dietary modification (low-FODMAP, elemental diets), and addressing underlying causes (anatomic abnormalities, gastroparesis, opioid use, achlorhydria). Recurrence is common — a meaningful minority of patients relapse within 6-12 months — and chronic SIBO can be frustrating to manage.
Peptide therapy has come up in functional medicine and gut health communities for SIBO, particularly for the mucosal damage and motility dysfunction that often accompany the condition. The peptides most discussed — BPC-157, KPV, and larazotide — target gut barrier function and mucosal repair rather than antimicrobial action against bacterial overgrowth itself. The honest framing: peptides do not replace rifaximin as primary antimicrobial therapy, but may support mucosal recovery, gut barrier function, and the motility dysfunction that often drives recurrent SIBO.
This page covers what's actually known about peptides for SIBO, the appropriate role alongside conventional antimicrobial and prokinetic therapy, and important caveats. It is informational, not medical advice.
Peptides discussed for SIBO
Larazotide
Tight Junction Regulator
A synthetic peptide that regulates intestinal tight junctions, in clinical trials for celiac disease and studied for leaky gut conditions.
Thymosin Alpha-1
Thymic Peptide
A thymic peptide approved in multiple countries for immune modulation, particularly in hepatitis and as a vaccine adjuvant.
BPC-157
Gastric Peptide
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
KPV
Anti-Inflammatory Tripeptide
A tripeptide fragment of alpha-MSH with potent anti-inflammatory properties, studied for inflammatory bowel disease and skin conditions.
How peptides target sibo
BPC-157 has substantial preclinical evidence for gastrointestinal mucosal protection and healing. Multiple animal studies demonstrate accelerated healing of gastric and intestinal mucosal injury, modulation of nitric oxide signaling, and protective effects against various gastrointestinal stressors. The mechanism translates plausibly to the mucosal damage that often coexists with SIBO — chronic bacterial overgrowth produces enterocyte damage, increased intestinal permeability, and inflammation that benefits from epithelial repair support. BPC-157 is the most-discussed peptide in functional medicine SIBO protocols.
KPV (the C-terminal tripeptide of α-MSH) has anti-inflammatory effects in intestinal epithelium and has been studied in colitis models. Its NF-κB inhibition and reduction of pro-inflammatory cytokine production in intestinal epithelial cells aligns with the inflammatory component of chronic SIBO. KPV is increasingly used in functional medicine practice for chronic gut inflammation.
Larazotide (a synthetic peptide tight-junction modulator) supports gut barrier function by reducing zonulin-mediated tight junction disassembly. While its primary research focus has been celiac disease, the mechanism applies to any condition with increased intestinal permeability — common in SIBO. Larazotide is investigational in the US but has been used in functional medicine and integrative gastroenterology contexts.
What peptides do not do: replace antimicrobial therapy. SIBO is fundamentally a bacterial overgrowth that requires reduction in bacterial load to achieve symptomatic and functional recovery. Rifaximin and adjunctive antibiotics remain primary therapy.
What the evidence shows
There are no randomized trials of any peptide for SIBO. The evidence is preclinical (BPC-157 in gut mucosal models, KPV in colitis models, larazotide in barrier function) plus functional medicine clinic case series. Conventional comparators have substantial evidence: rifaximin has multiple RCTs supporting it for hydrogen-dominant SIBO, with response rates of 40-65% per cycle. Methane-dominant SIBO/IMO responds to combination rifaximin plus neomycin in trials. Prokinetic therapy (low-dose erythromycin, prucalopride) has evidence for reducing recurrence by supporting migrating motor complex activity.
Peptide therapy is positioned as an adjunct to support the mucosal and barrier-function consequences of SIBO, not as antimicrobial primary therapy. The reasonable place for peptides is alongside antibiotic therapy and prokinetic support, particularly in chronic recurrent SIBO with documented mucosal damage and barrier dysfunction.
What to expect
Reports of subjective symptom improvement with BPC-157 (250-500 mcg twice daily, often by oral or sublingual route in functional medicine practice) over 4-8 weeks alongside rifaximin or after rifaximin therapy. KPV used similarly. Symptom improvement attributable to peptide versus the antibiotic versus the natural course is typically not separable.
What to NOT expect: SIBO eradication from peptides alone, replacement of antibiotic therapy, or quick fixes for chronic recurrent SIBO without addressing underlying causes (motility dysfunction, anatomic issues, dietary factors).
Important caveats
SIBO management should be coordinated by a gastroenterologist or functional medicine clinician familiar with the condition. Diagnosis requires breath testing; symptom-based 'SIBO suspicion' without testing leads to overdiagnosis. Underlying causes should be evaluated — particularly motility dysfunction, prior abdominal surgery, structural abnormalities, gastroparesis, opioid use, and chronic PPI use. Recurrent SIBO often reflects an unaddressed underlying driver.
None of the peptides discussed is FDA-approved for SIBO. BPC-157 was placed on FDA Section 503A 'Category 2' in 2023, restricting US compounding-pharmacy access. Larazotide is investigational in the US (failed primary endpoint in celiac disease Phase 3 in 2022, though further development continues for other GI indications). Rifaximin and conventional therapy remain primary.
Frequently asked questions
Can BPC-157 cure SIBO?
No. SIBO is a bacterial overgrowth requiring antimicrobial therapy (typically rifaximin) for primary treatment. BPC-157 supports mucosal healing and gut barrier function, which are commonly damaged in chronic SIBO, but it does not eradicate bacterial overgrowth. The reasonable role is as an adjunct to rifaximin and prokinetic therapy for mucosal recovery and barrier support.
Should I use peptides instead of rifaximin?
No. Rifaximin has substantial RCT evidence for SIBO with response rates of 40-65% per cycle and is FDA-approved for related GI indications. Peptides do not replace antimicrobial therapy. The appropriate use of peptides is alongside or after rifaximin treatment, not instead of it.
How do peptides help with SIBO?
BPC-157 supports gastrointestinal mucosal healing — chronic SIBO produces enterocyte damage, inflammation, and increased intestinal permeability that benefit from epithelial repair support. KPV provides anti-inflammatory action particularly relevant for chronic SIBO. Larazotide supports tight junction function for barrier recovery. None of these is antimicrobial; they support the mucosal consequences of SIBO rather than treating the underlying bacterial overgrowth.
Why does my SIBO keep coming back?
Recurrent SIBO usually reflects an unaddressed underlying driver — motility dysfunction (most common; the migrating motor complex normally clears the small bowel between meals), structural issues (adhesions, diverticula), anatomic factors (post-surgical anatomy), achlorhydria from chronic PPI use, or gastroparesis. Antibiotic therapy without addressing the underlying driver leads to predictable recurrence. Prokinetic therapy (low-dose erythromycin, prucalopride) and addressing the underlying cause are essential for reducing recurrence.
Are peptides safe for chronic SIBO?
BPC-157, KPV, and larazotide have generally clean safety signals in available data, but long-term safety in chronic recurrent use is not well characterized. None is FDA-approved for SIBO. Patients should use peptide therapy under clinician supervision alongside conventional antimicrobial and prokinetic care, with attention to addressing the underlying drivers of SIBO.
Part of these goals
Related conditions
Peptide families relevant to SIBO
Antimicrobial Peptides
The peptide family of host-defense antimicrobial peptides — LL-37 (the human cathelicidin), KPV (the alpha-MSH-derived anti-inflammatory tripeptide), lactoferricin (the lactoferrin-derived antimicrobial), DS-5, plus the broader research-tier cluster including tuftsin, hepcidin, and larazotide. Antimicrobial peptides are an active drug-development area for resistant infections, mucosal immunity, and inflammatory disease, with origins traceable to Michael Zasloff's 1987 discovery of the magainins.
Melanocortins
The peptide family of α-MSH analogs and selective melanocortin-receptor agonists — covering pigmentation (afamelanotide, melanotan-II), monogenic obesity (setmelanotide), and female sexual desire (bremelanotide / PT-141), plus the immunomodulatory KPV tripeptide and the cosmetic α-MSH analog nonapeptide-1.
Thymic Peptides
The peptide family derived from thymic tissue and its synthetic analogs — Thymosin α-1 (Zadaxin / thymalfasin, immune modulation), Thymosin β-4 (TB-500, tissue repair through actin sequestration), Thymalin (Russian-tradition thymic-extract preparation), Thymulin (zinc-dependent thymic hormone), and Thymagen (Khavinson-program synthetic thymic peptide). Two functional branches: α-family for immune function, β-family for actin-mediated tissue repair.
Stacks that overlap
- Thymosin Alpha-1 + KPV (The Immune & Gut Stack)
Pairs systemic immune modulation (Thymosin Alpha-1) with targeted gut anti-inflammatory action (KPV) for comprehensive immune and gastrointestinal support.
- KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW is a pre-mixed four-peptide compounded blend combining BPC-157 and TB-500 systemic repair, GHK-Cu collagen remodeling, and KPV anti-inflammatory coverage in a single 80 mg vial. It extends the popular GLOW formulation with an explicit anti-inflammatory layer.
Updated 2026-05-08